173 related articles for article (PubMed ID: 28645444)
41. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
42. Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.
Lesieur A; Thomas X; Nibourel O; Boissel N; Fenwarth L; De Botton S; Fournier E; Celli-Lebras K; Raffoux E; Recher C; Lambert J; Berthon C; Pigneux A; Itzykson R; Turlure P; Pautas C; Vargaftig J; Preudhomme C; Dombret H; Duployez N
Haematologica; 2021 Jun; 106(6):1767-1769. PubMed ID: 33299234
[TBL] [Abstract][Full Text] [Related]
43. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene.
Jeziskova I; Razga F; Toskova M; Dvorakova D; Timilsina S; Mayer J; Racil Z
Leuk Lymphoma; 2013 Apr; 54(4):867-70. PubMed ID: 22950897
[No Abstract] [Full Text] [Related]
44. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations.
Chou WC; Tang JL; Wu SJ; Tsay W; Yao M; Huang SY; Huang KC; Chen CY; Huang CF; Tien HF
Leukemia; 2007 May; 21(5):998-1004. PubMed ID: 17361227
[TBL] [Abstract][Full Text] [Related]
45. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
46. Mutant Enrichment with 3'-Modified Oligonucleotides (MEMO)-Quantitative PCR for Detection of NPM1 Mutations in Acute Myeloid Leukemia.
Shin SY; Ki CS; Kim HJ; Kim JW; Kim SH; Lee ST
J Clin Lab Anal; 2015 Sep; 29(5):361-5. PubMed ID: 25384962
[TBL] [Abstract][Full Text] [Related]
47. [Simultaneous detection of FLT3-ITD and NPM1 gene mutations in acute myeloid leukemia by double PCR].
Zhang ZC; Lu QY; Zhao JN; Chen YM; Li ZP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):717-20. PubMed ID: 21729557
[TBL] [Abstract][Full Text] [Related]
48. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
49. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
50. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression.
Kristensen T; Møller MB; Friis L; Bergmann OJ; Preiss B
Eur J Haematol; 2011 Nov; 87(5):400-8. PubMed ID: 21707751
[TBL] [Abstract][Full Text] [Related]
51. NPM1 Mutation Detection in Acute Myeloid Leukemia: A Method Comparison Study.
Azari-Yam A; Bagheri SD; Tavakkoly-Bazzaz J; Sarhaddi AB; Rejali L; Alimoghaddam K; Yaghmaie M; Ghavamzadeh A; Zeinali S
Genet Test Mol Biomarkers; 2016 Feb; 20(2):63-6. PubMed ID: 26666953
[TBL] [Abstract][Full Text] [Related]
52. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with
Shumilov E; Flach J; Joncourt R; Porret N; Wiedemann G; Novak U; Gfeller E; Jeker B; Amstutz U; Pabst T; Bacher U
Leuk Lymphoma; 2019 Oct; 60(10):2588-2590. PubMed ID: 30998101
[No Abstract] [Full Text] [Related]
53. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
[TBL] [Abstract][Full Text] [Related]
54. Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia.
Folta A; Sasinkova M; Durinikova A; Drncova M; Weinbergerova B; Mayer J; Jeziskova I
Mol Biol Rep; 2022 Aug; 49(8):8169-8172. PubMed ID: 35716280
[TBL] [Abstract][Full Text] [Related]
55. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
56. Minor BCR-ABL1-Positive Acute Myeloid Leukemia Associated With the NPM1 Mutation and FLT3 Internal Tandem Duplication.
Kim MJ; Ahn S; Jeong SH; Jang JH; Han JH; Choi JR; Cho SR
Ann Lab Med; 2016 May; 36(3):263-5. PubMed ID: 26915617
[No Abstract] [Full Text] [Related]
57. Monitoring minimal residual disease in AML: the right time for real time.
Jaeger U; Kainz B
Ann Hematol; 2003 Mar; 82(3):139-47. PubMed ID: 12634945
[TBL] [Abstract][Full Text] [Related]
58. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
59. Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
Kayser S; Walter RB; Stock W; Schlenk RF
Curr Hematol Malig Rep; 2015 Jun; 10(2):132-44. PubMed ID: 25994952
[TBL] [Abstract][Full Text] [Related]
60. Novel NPM1 mutation in the 3'-untranslated region identified in two patients with acute myeloid leukemia.
Abraham A; Karathedath S; Kumaraswamy V; Jayavelu AK; Mani S; Srivastava VM; Zhang W; Zhou T; George B; Srivastava A; Mathews V; Balasubramanian P
Leuk Lymphoma; 2014 Jun; 55(6):1421-4. PubMed ID: 23998253
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
